Without accurate information I have no means of determining a value.
I do think the cannabis industry is primed for growth and MCL has the business structure to take full advantage of that BUT the tendency for QBL to use grandiose verbiage or over inflate claims made in ANN's gives credence to them having over inflated their own idea of the value of 45% of MCL .
A lower estimation IMO would have had a much different reaction by the market and meant success all round.
I initially invested and hoped for preference in the IPO of MCL.. with an IPO comes a full prospectus .. seeing in detail the scope of MCL in part covered in this latest ANN but the numbers are missing. Hopefully as you say the quarterly and any hemp info released will address this.
- Forums
- ASX - By Stock
- CGB
- Ann: Q&A on the merger of QBL MCL and Medcan
Ann: Q&A on the merger of QBL MCL and Medcan, page-333
-
- There are more pages in this discussion • 216 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add CGB (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online